MRI对乳腺癌药物治疗所致心脏毒性的早期检测
Early Detection of MRI Cardiac Toxicity Caused by the Treatment of Breast Cancer Drugs
DOI: 10.12677/ACM.2023.133677, PDF,    科研立项经费支持
作者: 王 滕*, 王翠艳：山东大学，山东 济南；山东省立医院放射科，山东 济南
关键词: 磁共振成像；乳腺癌；心脏毒性；化学治疗；靶向治疗；Magnetic Resonance Imaging； Breast Cancer； Cardiotoxicity； Chemotherapy； Targeted Therapy
摘要: 有数据显示，乳腺癌已占据女性癌症发病率和死亡率的首位，但得益于医疗水平的进步，患者的生存时间整体延长。然而代价是心脏毒性和心功能不全的风险增加，有必要引起医生足够的警惕和重视。心脏磁共振(Cardiac Magnetic Resonance, CMR)可显示心脏的结构、功能及心肌组织特征，其先进的测量应变及mapping技术可早期发现心肌损伤，包括心肌水肿、纤维化及亚临床心肌功能改变等。总之心脏MRI可早期发现乳腺癌治疗所致心脏毒性，并对后续的监测、疗效评估及预后判断具有重要的临床价值。本文就MRI对乳腺癌药物治疗所致心脏毒性的早期检测作一综述。
Abstract: Some data show that breast cancer has occupied the first place in terms of cancer morbidity and mortality in women, but due to medical advances, patients have an overall longer survival time. The cost, however, is an increased risk of cardiotoxicity and cardiac insufficiency, warranting sufficient vigilance and attention from physicians. Cardiac Magnetic Resonance (CMR) reveals the structure, function, and myocardial tissue characteristics of the heart, and its advanced strain and mapping techniques allow for early detection of myocardial injury, including myocardial edema, fibrosis, and subclinical myocardial functional changes. In conclusion, cardiac MRI can provide early detection of cardiotoxicity due to breast cancer treatment and is clinically important for follow-up monitoring, efficacy assessment, and prognosis. In this paper, we review the early detection of cardiotoxicity due to breast cancer drug therapy by MRI.
文章引用：王滕, 王翠艳. MRI对乳腺癌药物治疗所致心脏毒性的早期检测[J]. 临床医学进展, 2023, 13(3): 4726-4733. https://doi.org/10.12677/ACM.2023.133677

参考文献

[1] 邹小农, 贾漫漫, 王鑫, 支修益. 《2020全球癌症报告》要点解读[J]. 中国胸心血管外科临床杂志, 2021, 28(1): 11-18.
[2] Chen, W., Zheng, R., Baade, P.D., Zhang, S., Zeng, H., Bray, F., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. [Google Scholar] [CrossRef] [PubMed]
[3] van Dalen, E.C., van der Pal, H.J.H., Kok, W.E.M., Caron, H.N. and Kremer, L.C.M. (2006) Clinical Heart Failure in a Cohort of Chil-dren Treated with Anthracyclines: A Long-Term Follow-Up Study. European Journal of Cancer, 42, 3191-3198. [Google Scholar] [CrossRef] [PubMed]
[4] Mulrooney, D.A., Yeazel, M.W., Kawashima, T., Mertens, A.C., Mitby, P., Stovall, M., et al. (2009) Cardiac Outcomes in a Cohort of Adult Survivors of Childhood and Adolescent Cancer: Retrospective Analysis of the Childhood Cancer Survivor Study Cohort. BMJ, 339, Article No. b4606. [Google Scholar] [CrossRef] [PubMed]
[5] Herrmann, J. (2020) Adverse Cardiac Effects of Cancer Therapies: Cardio-toxicity and Arrhythmia. Nature Reviews Cardiology, 17, 474-502. [Google Scholar] [CrossRef] [PubMed]
[6] McGowan, J.V., Chung, R., Maulik, A., Piotrowska, I., Walker, J.M. and Yellon, D.M. (2017) Anthracycline Chemotherapy and Cardiotoxicity. Cardiovascular Drugs and Therapy, 31, 63-75. [Google Scholar] [CrossRef] [PubMed]
[7] Shabalala, S., Muller, C.J.F., Louw, J. and Johnson, R. (2017) Polyphenols, Autophagy and Doxorubicin-Induced Cardiotoxicity. Life Sciences, 180, 160-170. [Google Scholar] [CrossRef] [PubMed]
[8] Ferreira de Souza, T., Quinaglia AC Silva, T., Osorio Costa, F., Shah, R., Neilan, T. G., Velloso, L., et al. (2018) Anthracycline Therapy Is Associated with Cardiomyocyte Atrophy and Pre-clinical Manifestations of Heart Disease. JACC: Cardiovascular Imaging, 11, 1045-1055. [Google Scholar] [CrossRef] [PubMed]
[9] Swain, S.M., Whaley, F.S. and Ewer, M.S. (2003) Congestive Heart Failure in Patients Treated with Doxorubicin: A Retrospective Analysis of Three Trials. Cancer, 97, 2869-2879. [Google Scholar] [CrossRef] [PubMed]
[10] Bristow, M.R., Thompson, P.D., Martin, R.P., Mason, J.W., Billingham, M.E. and Harrison, D.C. (1978) Early Anthracycline Cardiotoxicity. The American Journal of Medicine, 65, 823-832. [Google Scholar] [CrossRef] [PubMed]
[11] Gottdiener, J.S., Appelbaum, F.R., Ferrans, V.J., Deisseroth, A. and Ziegler, J. (1981) Cardiotoxicity Associated with High-Dose Cyclophosphamide Therapy. Archives of Internal Medicine, 141, 758-763. [Google Scholar] [CrossRef] [PubMed]
[12] Zamorano, J.L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., et al. (2016) 2016 ESC Position Paper on Cancer Treatments and Cardio-vascular Toxicity Developed under the Auspices of the ESC Committee for Practice Guidelines: The Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC). European Heart Journal, 37, 2768-2801. [Google Scholar] [CrossRef] [PubMed]
[13] Ewer, M.S. and Ewer, S.M. (2015) Cardiotoxicity of anticancer treatments. Nature Reviews Cardiology, 12, 547-558. [Google Scholar] [CrossRef] [PubMed]
[14] Martel, S., Maurer, C., Lambertini, M., Pondé, N. and De Azambuja, E. (2017) Breast Cancer Treatment-Induced Cardiotoxicity. Expert Opinion on Drug Safety, 16, 1021-1038. [Google Scholar] [CrossRef] [PubMed]
[15] Fanous, I. and Dillon, P. (2016) Cancer Treatment-Related Cardiac Toxicity: Prevention, Assessment and Management. Medical Oncology, 33, Article No. 84. [Google Scholar] [CrossRef] [PubMed]
[16] Jerusalem, G., Moonen, M., Freres, P. and Lancellotti, P. (2015) The European Association of Cardiovascular Imaging/heart Failure Association Cardiac Oncology Toxicity Registry: Long-Term Benefits for Breast Cancer Treatment. Future Oncology, 11, 2791-2794. [Google Scholar] [CrossRef] [PubMed]
[17] Giordano, G., Spagnuolo, A., Olivieri, N., Corbo, C., Campagna, A., Spagnoletti, I., et al. (2016) Cancer Drug Related Cardiotoxicity during Breast Cancer Treatment. Expert Opinion on Drug Safety, 15, 1063-1074. [Google Scholar] [CrossRef] [PubMed]
[18] Pondé, N.F., Lambertini, M. and de Azambuja, E. (2016) Twenty Years of Anti-HER2 Therapy-Associated Cardiotoxicity. ESMO Open, 1, e000073. [Google Scholar] [CrossRef] [PubMed]
[19] Barish, R., Gates, E. and Barac, A. (2019) Trastuzumab-Induced Cardiomyopathy. Cardiology Clinics, 37, 407-418. [Google Scholar] [CrossRef] [PubMed]
[20] Dunet, V., Schwitter, J., Meuli, R. and Beigelman-Aubry, C. (2016) Incidental Extracardiac Findings on Cardiac MR: Systematic Review and Meta-Analysis. Journal of Magnetic Resonance Imaging, 43, 929-939. [Google Scholar] [CrossRef] [PubMed]
[21] Lambert, J., Lamacie, M., Thampinathan, B., Altaha, M.A., Esmaeilzadeh, M., Nolan, M., et al. (2020) Variability in Echocardiography and MRI for Detection of Cancer Therapy Cardiotoxicity. Heart, 106, 817-823. [Google Scholar] [CrossRef] [PubMed]
[22] Halliday, B.P., Senior, R. and Pennell, D.J. (2021) Assessing Left Ventricular Systolic Function: From Ejection Fraction to Strain Analysis. European Heart Journal, 42, 789-797. [Google Scholar] [CrossRef] [PubMed]
[23] Plana, J.C., Galderisi, M., Barac, A., Ewer, M.S., Ky, B., Scher-rer-Crosbie, M., et al. (2014) Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovas-cular Imaging. Journal of the American Society of Echocardiography, 27, 911-939. [Google Scholar] [CrossRef] [PubMed]
[24] Ewer, M.S., Ali, M.K., Mackay, B., Wallace, S., Valdivieso, M., Legha, S.S., et al. (1984) A Comparison of Cardiac Biopsy Grades and Ejection Fraction Estimations in Patients Receiv-ing Adriamycin. Journal of Clinical Oncology, 2, 112-117. [Google Scholar] [CrossRef] 
[25] Jolly, M.-P., Jordan, J.H., Meléndez, G.C., McNeal, G.R., D’Agostino, R.B. and Hundley, W.G. (2017) Automated Assess-ments of Circumferential Strain from Cine CMR Correlate with LVEF Declines in Cancer Patients Early after Receipt of Cardio-Toxic Chemotherapy. Journal of Cardiovascular Magnetic Resonance, 19, Article No. 59. [Google Scholar] [CrossRef] [PubMed]
[26] Gottbrecht, M., Kramer, C.M. and Salerno, M. (2019) Native T1 and Extracellular Volume Measurements by Cardiac MRI in Healthy Adults: A Meta-Analysis. Radiology, 290, 317-326. [Google Scholar] [CrossRef] [PubMed]
[27] Giusca, S., Korosoglou, G., Montenbruck, M., Gersak, B., Schwarz, A.K., Esch, S., et al. (2021) Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardi-al Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-up. Circulation: Cardiovascular Imaging, 14, e012459. [Google Scholar] [CrossRef] 
[28] Pituskin, E., Mackey, J.R., Koshman, S., Jassal, D., Pitz, M., Haykowsky, M.J., et al. (2017) Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. Journal of Clinical Oncology, 35, 870-877. [Google Scholar] [CrossRef] 
[29] Neilan, T.G., Coelho-Filho, O.R., Pena-Herrera, D., Shah, R.V., Jerosch-Herold, M., Francis, S.A., et al. (2012) Left Ventricular Mass in Patients with a Cardiomyopathy after Treatment with Anthracyclines. The American Journal of Cardiology, 110, 1679-1686. [Google Scholar] [CrossRef] [PubMed]
[30] Barthur, A., Brezden-Masley, C., Connelly, K.A., Dhir, V., Chan, K.K.W., Haq, R., et al. (2017) Longitudinal Assessment of Right Ventricular Structure and Function by Cardio-vascular Magnetic Resonance in Breast Cancer Patients Treated with Trastuzumab: A Prospective Observational Study. Journal of Cardiovascular Magnetic Resonance, 19, Article No. 44. [Google Scholar] [CrossRef] [PubMed]
[31] Ylänen, K., Poutanen, T., Savikurki-Heikkilä, P., Rinta-Kiikka, I., Eerola, A. and Vettenranta, K. (2013) Cardiac Magnetic Resonance Imaging in the Evaluation of the Late Effects of Anthracyclines Among Long-Term Survivors of Childhood Cancer. Journal of the American College of Cardiology, 61, 1539-1547. [Google Scholar] [CrossRef] [PubMed]
[32] Chang, W.-T., Shih, J.-Y., Feng, Y.-H., Chiang, C.-Y., Kuo, Y.H., Chen, W.-Y., et al. (2016) The Early Predictive Value of Right Ventricular Strain in Epirubicin-Induced Cardiotoxicity in Patients with Breast Cancer. Acta Cardiological Sinica, 32, 550-559.
[33] Chen, L., Huang, J., Wu, W., Ta, S. and Xie, X. (2019) The Impact of Right Ventricular Function on Prognosis in Patients with Stage III Non-Small Cell Lung Cancer after Concurrent Chemoradiotherapy. The International Journal of Cardiovascular Imaging, 35, 1009-1017. [Google Scholar] [CrossRef] [PubMed]
[34] de Ville de Goyet, M., Brichard, B., Robert, A., Renard, L., Veyckemans, F., Vanhoutte, L. and Moniotte, S. (2015) Prospective Cardiac MRI for the Analysis of Biventricular Function in Children Undergoing Cancer Treatments. Pediatric Blood & Cancer, 62, 867-874. [Google Scholar] [CrossRef] [PubMed]
[35] Evin, M., Cluzel, P., Lamy, J., Rosenbaum, D., Kusmia, S., Defrance, C., et al. (2015) Assessment of Left Atrial Function by Mri Myocardial Feature Tracking. Journal of Magnetic Resonance Im-aging, 42, 379-389. [Google Scholar] [CrossRef] [PubMed]
[36] Messroghli, D.R., Moon, J.C., Ferreira, V.M., Grosse-Wortmann, L., He, T., Kellman, P., et al. (2017) Clinical Recommendations for Cardiovascular Magnetic Resonance Mapping of T1, T2, T2* and Extracellular Volume: A Consensus Statement by the Society for Cardiovascular Magnetic Resonance (SCMR) En-dorsed by the European Association for Cardiovascular Imaging (EACVI). Journal of Cardiovascular Magnetic Reso-nance, 19, Article No. 75. [Google Scholar] [CrossRef] [PubMed]
[37] Soufer, A. and Baldassarre, L.A. (2019) The Role of Cardiac Magnetic Resonance Imaging to Detect Cardiac Toxicity from Cancer Therapeutics. Current Treatment Options in Car-diovascular Medicine, 21, Article No. 28. [Google Scholar] [CrossRef] [PubMed]
[38] Park, C.J., Branch, M.E., Vasu, S. and Melendez, G.C. (2020) The Role of Cardiac MRI in Animal Models of Cardiotoxicity: Hopes and Challenges. Journal of Cardiovascular Translational Research, 13, 367-376. [Google Scholar] [CrossRef] [PubMed]
[39] Haslbauer, J.D., Lindner, S., Valbuena-Lopez, S., Zainal, H., Zhou, H., D’Angelo, T., et al. (2019) CMR Imaging Biosignature of Cardiac Involvement Due to Cancer-Related Treat-ment by T1 and T2 Mapping. International Journal of Cardiology, 275, 179-186. [Google Scholar] [CrossRef] [PubMed]
[40] Hong, Y.J., Park, H.S., Park, J.K., Han, K., Park, C.H., Kim, T.K., et al. (2017) Early Detection and Serial Monitoring of Anthracycline-Induced Cardiotoxicity Using T1-Mapping Cardiac Magnetic Resonance Imaging: An Animal Study. Scientific Reports, 7, Article No. 2663. [Google Scholar] [CrossRef] [PubMed]
[41] Galán-Arriola, C., Lobo, M., Vílchez-Tschischke, J.P., López, G.J., de Molina-Iracheta, A., Pérez-Martínez, C., et al. (2019) Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity. Journal of the American College of Cardiology, 73, 779-791. [Google Scholar] [CrossRef] [PubMed]
[42] Modi, K., Joppa, S., Chen, K.-H.A., Athwal, P.S.S., Okasha, O., Velangi, P.S., et al. (2020) Myocardial Damage Assessed by Late Gadolinium Enhancement on Cardiovascular Magnetic Resonance Imaging in Cancer Patients Treated with Anthracyclines and/or Trastuzumab. European Heart Jour-nal-Cardiovascular Imaging, 22, 427-434. [Google Scholar] [CrossRef] [PubMed]
[43] Lightfoot, J.C., D’Agostino Jr., R.B., Hamilton, C.A., Jordan, J., Torti, F.M., Kock, N.D., et al. (2010) Novel Approach to Early Detection of Doxorubicin Cardiotoxicity by Gadolini-um-Enhanced Cardiovascular Magnetic Resonance Imaging in an Experimental Model. Circulation: Cardiovascular Im-aging, 3, 550-558. [Google Scholar] [CrossRef] 
[44] Varricchi, G., Ameri, P., Cadeddu, C., Ghigo, A., Ma-donna, R., Marone, G., et al. (2018) Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. Frontiers in Physiology, 9, Article 167. [Google Scholar] [CrossRef] [PubMed]
[45] Greenwood, J.P., Maredia, N., Younger, J.F., Brown, J.M., Nixon, J., Everett, C.C., et al. (2012) Cardiovascular Magnetic Resonance and Single-Photon Emission Computed Tomography for Diagnosis of Coronary Heart Disease (CE-MARC): A Prospective Trial. Lancet, 379, 453-460. [Google Scholar] [CrossRef] 
[46] Lipinski, M.J., McVey, C.M., Berger, J.S., Kramer, C.M. and Salerno, M. (2013) Prognostic Value of Stress Cardiac Magnetic Resonance Imaging in Patients with Known or Suspected Coronary Artery Disease: A Systematic Review and Meta-Analysis. Journal of the American College of Car-diology, 62, 826-838. [Google Scholar] [CrossRef] [PubMed]
[47] Schwitter, J., Wacker, C.M., Wilke, N., Al-Saadi, N., Sauer, E., Huettle, K., et al. (2013) MR-IMPACT II: Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coro-nary Artery Disease Trial: Perfusion-Cardiac Magnetic Resonance vs. Single-Photon Emission Computed Tomography for the Detection of Coronary Artery Disease: A Comparative Multicentre, Multivendor Trial. European Heart Journal, 34, 775-781. [Google Scholar] [CrossRef] [PubMed]
[48] Pack, N.A. and DiBella, E.V.R. (2010) Comparison of Myocardial Perfusion Estimates from Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Four Quantitative Analysis Methods. Magnetic Resonance in Medicine, 64, 125-137. [Google Scholar] [CrossRef] [PubMed]
[49] Nguyen, V.B.L. (2018) Stress Cardiovascular Magnetic Resonance for Evaluation of Antineoplastic Associated Cardiotoxicity in a Re-al-World Cohort of Breast Cancer Patients. Society of Cardiovascular Magnetic Resonance Scientific Sessions.
[50] Liu, A., Wijesurendra, R.S., Liu, J.M., Greiser, A., Jerosch-Herold, M., Forfar, J.C., et al. (2018) Gadolinium-Free Cardiac MR Stress T1-Mapping to Distinguish Epicardial from Microvascular Coronary Disease. Journal of the American Col-lege of Cardiology, 71, 957-968. [Google Scholar] [CrossRef] [PubMed]
[51] Boutouyrie, P., Tropeano, A.I., Asmar, R., Gautier, I., Benetos, A., Lacolley, P., et al. (2002) Aortic Stiffness Is an Independent Predictor of Primary Coronary Events in Hypertensive Patients: A Longitudinal Study. Hypertension, 39, 10-15. [Google Scholar] [CrossRef] [PubMed]
[52] Chaosuwannakit, N., D’Agostino, R., Hamilton, C.A., Lane, K.S., Ntim, W.O., Lawrence, J., et al. (2010) Aortic Stiffness Increases upon Receipt of Anthracycline Chemotherapy. Journal of Clinical Oncology, 28, 166-172. [Google Scholar] [CrossRef] 
[53] Drafts, B.C., Twomley, K.M., D’Agostino, R., Lawrence, J., Avis, N., Ellis, L.R., et al. (2013) Low to Moderate Dose Anthracycline-Based Chemotherapy Is Associated with Early Non-invasive Imaging Evidence of Subclinical Cardiovascular Disease. JACC: Cardiovascular Imaging, 6, 877-885. [Google Scholar] [CrossRef] [PubMed]
[54] Grover, S., Lou, P.W., Bradbrook, C., Cheong, K., Kotasek, D., Leong, D.P., et al. (2015) Early and Late Changes in Markers of Aortic Stiffness with Breast Cancer Therapy. Internal Medicine Journal, 45, 140-147. [Google Scholar] [CrossRef] [PubMed]

为你推荐